Clinical Trials Logo

Clinical Trial Summary

A total of up to 90 participants may be given H1N1 influenza challenge virus. In Part A, 40 participants will be randomly allocated to one of two groups to be given one of two virus doses (Virus Dose 1 or Virus Dose 2). Based on the outcome of Part A, participants in Part B, may be given Virus Dose 1, Virus Dose 2, or another virus dose (e.g., Virus Dose 3)


Clinical Trial Description

Influenza viruses are associated with significant human disease and cause annual epidemics during autumn and winter. Although most people recover within 1 to 2 weeks without requiring medical attention, seasonal influenza yearly results in approximately 3 to 5 million cases of severe illness and up to 500,000 deaths worldwide, particularly among the very young, elderly, and chronically ill. The H1N1 virus used for the challenge virus originated from a cell-culture derived candidate vaccine virus (ccCVV), provided by the Centers for Disease Control an Prevention (CDC) in the USA. In Part A, 40 participants will be randomly allocated to one of two groups to be given one of two virus doses (Virus Dose 1 or Virus Dose 2). Based on the outcome of Part A, participants in Part B, may be given Virus Dose 1, Virus Dose 2, or another virus dose (e.g., Virus Dose 3) ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05572450
Study type Interventional
Source Hvivo
Contact
Status Completed
Phase N/A
Start date September 7, 2022
Completion date December 19, 2022

See also
  Status Clinical Trial Phase
Completed NCT06385821 - A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus Phase 3
Completed NCT03315104 - Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A Phase 2
Active, not recruiting NCT04850898 - Study of SAB-176 in Healthy Adult Participants Phase 2
Completed NCT03743688 - Kinetics of the Immune Response to Inactivated Influenza Vaccine in Healthy Adults
Recruiting NCT04499378 - Tomographic Findings in COVID-19 and Influenza H1N1